Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: Panobinostat and Ruxolitinib in Myelofibrosis
NCT01693601Phase 2Completed
- Sponsor
- John Mascarenhas
- Start
- Jan 2013
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in myelofibrosis (MF), sponsored by John Mascarenhas. Primary endpoints: Number of Patients That Achieve Stable Disease or Clinical Improvement at 6 months and Number of Participants Who Experienced Dose-Limiting Toxicities. Started Jan 2013; status: completed.
02
Drugs
panobinostat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01693601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693601.